Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | LSS | P48449 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | TPH1 | P17752 | 2/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3630497 | 0.90 | LSS (0.55) | PPARAEPHX2PPARGKMT2ALSS | |
| Trifluoroacetic Acid SCHEMBL3631651 | 0.87 | KMT2A (0.51) | PPARAEPHX2PPARGKMT2ALSS | |
| SCHEMBL2629356 | 0.85 | LSS (0.59) | PPARAEPHX2PPARGKMT2ALSS | |
| Cadaverine Tartrate SCHEMBL9937385 | 0.83 | KMT2A (0.53) | PPARAEPHX2PPARGADAMTS4MMP13 | |
| Cadaverine Tartrate SCHEMBL9938548 | 0.83 | KMT2A (0.55) | ADAMTS4MMP13KMT2AHDAC1HDAC3 | |
| Cadaverine Tartrate SCHEMBL9938634 | 0.83 | KMT2A (0.53) | ADAMTS4MMP13KMT2AHDAC1HDAC3 | |
| SCHEMBL5926892 | 0.81 | EPHX2 (0.57) | PPARAEPHX2PPARGLSSHDAC1 | |
| Cadaverine Tartrate SCHEMBL9936743 | 0.81 | ADAMTS4 (0.53) | ADAMTS4MMP13KMT2AHDAC1HDAC3 | |
| Cadaverine Tartrate SCHEMBL3633165 | 0.78 | ADAMTS4 (0.48) | ADAMTS4MMP13KMT2AHDAC1HDAC3 | |
| SCHEMBL5926895 | 0.77 | MTTP (0.48) | PPARAEPHX2PPARGLSSHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012080497-A2 | METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | WO | disclosed |
| EP-2152865-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008140449-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140450-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-20 | — | — | WO | disclosed |